Methods of treating cancer, infectious disease, and autoimmune disease using CXC chemokines
View Patent ↗The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using CXC chemokines and the receptors to which they agonize. It has been found that certain chemokines, including CXCL4, CXCL9, CXCL10, and CXCL12 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment and prevention.
1. A method of activating an immune response in a subject, comprising administering to the subject a therapeutically effective amount of a chemokine CXCL4, wherein the chemokine CXCL4 potentiates the response of toll-like receptor (TLR) 9 to produce interferon-α in plasmacytoid dendritic cells from the subject and the activation of the immune response is beneficial to treating cancer.
2. The method of claim 1 , wherein the cancer is chosen from the group consisting of lung cancer, colon cancer, melanoma, pancreatic cancer, mammary cancer, prostate cancer, breast cancer, ovarian cancer, basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, cervical cancer, colon and rectum cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, cancer of the head and neck, kidney cancer, larynx cancer, liver cancer, fibroma, neuroblastoma, oral cavity cancer, skin cancer, testicular cancer, thyroid cancer, uterine cancer, medulloblastoma, sarcoma, squamous cell carcinoma, and lymphoma.
3. The method of claim 1 , wherein the CXCL4 is administered by injection directly into a tumor in the subject.
4. The method of claim 1 , further comprising administering to the subject an agonist of TLR9.
5. The method of claim 4 , wherein the agonist is chosen from the group consisting of CpG nucleotides, CpG-A, CpG-B and CpG-C.
6. The method of claim 4 , further comprising administering to the subject a checkpoint inhibitor.
7. The method of claim 6 , wherein the checkpoint inhibitor inhibits a protein chosen from the group consisting of CTLA-4, PD-L1, PD-L2, and PD-1.
8. The method of claim 1 , wherein the CXCL4 is administered via the administration of plasmacytoid dendritic cells into tumor tissue in the subject, wherein the plasmacytoid dendritic cells have been contacted ex vivo with the chemokine peptide or protein and further contacted with an agonist of TLR9.
9. The method of claim 8 , wherein the plasmacytoid dendritic cells were obtained from the subject.
10. The method of claim 8 , wherein the TLR9 agonist is chosen from the group consisting of CpG nucleotides, CpG-A, CpG-B and CpG-C.